Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | METAP2 | P50579 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12828080 | 0.93 | CA1 (0.42) | CA1CA2CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL179467 | 0.84 | CA2 (0.50) | CA1CA2CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL29436012 | 0.84 | CA2 (0.50) | CA1CA2CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL13918953 | 0.81 | KDM4E (0.49) | CA1CA2CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL12390582 | 0.79 | PDE2A (0.51) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL25530871 | 0.79 | CA1 (0.40) | CA1CA2CA9ALDH1A1CYP2C19 | |
| SCHEMBL15803005 | 0.79 | KDM4E (0.40) | CA1CA2CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL10064792 | 0.79 | PDE2A (0.41) | CA1CA2CA9ALDH1A1HSD17B10 | |
| SCHEMBL10064802 | 0.78 | NOTUM (0.41) | CA1CA2CA9ALDH1A1SMN1; SMN2 | |
| SCHEMBL12828082 | 0.78 | ALDH1A1 (0.43) | CA1CA2CA9ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10689381-B2 | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2020-06-23 | — | — | US | disclosed |
| US-20190119277-A1 | VINBLASTINE 20' AMIDES: SYNTHETIC ANALOGS THAT MAINTAIN OR IMPROVE POTENCY AND SIMULTANEOUSLY OVERCOME Pgp-DERIVED EFFLUX AND RESISTANCE | THE SCRIPPS RESEARCH INSTITUTE | 2019-04-25 | — | — | US | disclosed |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | KALYPSYS, INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10689381-B2 | Vinblastine 20″ amides: synthetic analogs that maintain or improve potency and simultaneously overcome Pgp-derived efflux and resistance | ABCG2, ABCC1, GLS | CA1 1108/4885CA2 1141/4885CA9 685/4885 |
| US-20090227599-A1 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR | PPARG, PPARA, PPARD | CA1 4311/4885CA2 3525/4885CA9 4390/4885 |
| US-20190119277-A1 | VINBLASTINE 20' AMIDES: SYNTHETIC ANALOGS THAT MAINTAIN OR IMPROVE POTENCY AND SIMULTANEOUSLY OVERCOME Pgp-DERIVED EFFLUX AND RESISTANCE | ABCG2, ABCC1, GLS | CA1 1128/4885CA2 1178/4885CA9 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.